WW International, Inc. Announces Third Quarter 2024 Results
WW International reported Q3 2024 results with revenues of $192.9 million, down 10.2% year-over-year. The company posted an operating loss of $39.0 million compared to operating income of $30.6 million in the prior year. End of Period Subscribers decreased 8.8% to 3.7 million. Clinical Subscribers grew 71.5% to 78,000. Adjusted gross margin improved to 69.1%. The company recorded non-cash impairment charges of $57.0 million for franchise rights. WW reiterated its full year 2024 guidance, expecting year-end subscribers of at least 3.1 million and revenue of at least $770.0 million.
WW International ha riportato i risultati del terzo trimestre 2024 con ricavi di 192,9 milioni di dollari, in calo del 10,2% rispetto all’anno precedente. L’azienda ha registrato una perdita operativa di 39,0 milioni di dollari rispetto a un utile operativo di 30,6 milioni di dollari nello stesso trimestre dell’anno scorso. Gli abbonati al termine del periodo sono diminuiti dell'8,8%, raggiungendo 3,7 milioni. Gli abbonati clinici sono aumentati del 71,5%, raggiungendo 78.000. Il margine lordo rettificato è migliorato, arrivando al 69,1%. L’azienda ha registrato oneri non monetari di riduzione di valore dei diritti di franchising per un totale di 57,0 milioni di dollari. WW ha confermato le sue previsioni per l'intero anno 2024, prevedendo un numero di abbonati di almeno 3,1 milioni e ricavi di almeno 770,0 milioni di dollari.
WW International reportó resultados del tercer trimestre de 2024 con ingresos de $192.9 millones, una disminución del 10.2% interanual. La compañía registró una pérdida operativa de $39.0 millones en comparación con un ingreso operativo de $30.6 millones en el año anterior. Los suscriptores al final del período disminuyeron un 8.8% a 3.7 millones. Los suscriptores clínicos crecieron un 71.5% a 78,000. El margen bruto ajustado mejoró al 69.1%. La compañía registró cargos por deterioro no monetario de $57.0 millones por derechos de franquicia. WW reiteró su pronóstico para el año 2024, esperando al menos 3.1 millones de suscriptores y ingresos de al menos $770.0 millones.
WW International은 2024년 3분기 결과를 보고하며 수익이 $192.9 백만으로 전년 대비 10.2% 감소했다고 밝혔습니다. 회사는 전년 동기 30.6 백만 달러의 운영 수익에 비해 $39.0 백만의 운영 손실을 기록했습니다. 기간 종료 시점의 가입자 수는 8.8% 감소하여 3.7 백만에 이르렀습니다. 임상 가입자는 71.5% 증가해 78,000명에 도달했습니다. 조정된 총 마진은 69.1%로 개선되었습니다. 회사는 프랜차이즈 권리에 대해 57.0 백만 달러의 비현금 손상 비용을 기록했습니다. WW는 2024년 전체 연도 가이드를 재확인하며 연말 가입자가 최소 3.1 백만 명, 수익이 최소 770.0 백만 달러에 이를 것으로 예상하고 있습니다.
WW International a annoncé ses résultats pour le troisième trimestre 2024 avec des revenus de 192,9 millions de dollars, en baisse de 10,2% par rapport à l'année précédente. L'entreprise a enregistré une perte d'exploitation de 39,0 millions de dollars contre un bénéfice d'exploitation de 30,6 millions de dollars l'année précédente. Le nombre d'abonnés à la fin de la période a diminué de 8,8% pour atteindre 3,7 millions. Le nombre d'abonnés cliniques a augmenté de 71,5% pour atteindre 78 000. La marge brute ajustée a été améliorée à 69,1%. L'entreprise a enregistré des charges de dépréciation non monétaires de 57,0 millions de dollars pour des droits de franchise. WW a réaffirmé ses prévisions pour l'année 2024, s'attendant à avoir au moins 3,1 millions d'abonnés et des revenus d'au moins 770,0 millions de dollars.
WW International hat die Ergebnisse für das 3. Quartal 2024 veröffentlicht, mit Einnahmen von 192,9 Millionen US-Dollar, was einem Rückgang von 10,2% im Vergleich zum Vorjahr entspricht. Das Unternehmen verzeichnete einen operativen Verlust von 39,0 Millionen US-Dollar, im Vergleich zu einem operativen Gewinn von 30,6 Millionen US-Dollar im Vorjahr. Die Zahl der Abonnenten am Ende des Zeitraums verringerte sich um 8,8% auf 3,7 Millionen. Die klinischen Abonnenten nahmen um 71,5% auf 78.000 zu. Die bereinigte Bruttomarge verbesserte sich auf 69,1%. Das Unternehmen verzeichnete nicht zahlungswirksame Wertminderungsaufwendungen in Höhe von 57,0 Millionen US-Dollar für Franchise-Rechte. WW bestätigte seine Gesamtjahresprognose für 2024 und erwartet zum Jahresende mindestens 3,1 Millionen Abonnenten und Einnahmen von mindestens 770,0 Millionen US-Dollar.
- Clinical Subscribers grew 71.5% year-over-year
- Adjusted gross margin improved to 69.1% from 66.2%
- Clinical Subscription Revenues increased 90.7% to $19.1 million
- Total revenues declined 10.2% to $192.9 million
- Operating loss of $39.0 million vs income of $30.6 million last year
- End of Period Subscribers decreased 8.8% to 3.7 million
- Recorded $57.0 million in non-cash impairment charges
- Digital and Workshops + Digital businesses showed declining recruitments
Insights
Q3 2024 results reveal significant challenges at WeightWatchers, with concerning metrics across multiple fronts. Revenue declined 10.2% to
The bright spot is the Clinical segment (formerly Sequence) showing
The liquidity position appears tight with only
- End of Period Subscribers of 3.7 million
- Revenues of
$192.9 million - Gross margin of
67.1% ; adjusted gross margin of69.1% - Operating Loss of
$39.0 million ; adjusted operating income of$35.7 million
NEW YORK, Nov. 06, 2024 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“WeightWatchers,” “WW,” or the “Company”) today announced its results for the third quarter of fiscal 2024.
“For over six decades, WeightWatchers has been the trusted leader in weight management, offering a full spectrum of science-backed, proven weight management solutions. With our expanded clinical offering, iconic trusted brand, and global community of members, we are well-equipped to succeed in today’s rapidly evolving market,” said Tara Comonte, Interim CEO. “We do, however, have significant work to do to better unify our solutions and enhance our member experience. I am fully committed to leading our team through this next phase, as we seek to drive meaningful progress in these strategic priorities and return the Company to sustainable growth.”
“The execution of our cost reduction initiatives continues to yield results, including another quarter of record adjusted gross margin,” said Heather Stark, the Company’s CFO. “We remain on track to deliver on our 2024 adjusted operating income guidance and deliver on our overall cost savings targets. Our current actions are driving improved profitability and liquidity as we work to turn around the business.”
Q3 2024 Consolidated Results
| % Change | |||||||||||||
| Three Months Ended | Adjusted for | ||||||||||||
| September 28, | September 30, | Constant | |||||||||||
| 2024 | 2023 | % Change | Currency(1) | ||||||||||
| (in millions except percentages and per share amounts) | |||||||||||||
| Subscription Revenues, net | (6.0 | %) | (6.4 | %) | |||||||||
| Other Revenues, net(2) | 1.6 | 11.4 | (85.6 | %) | (85.7 | %) | |||||||
| Revenues, net | (10.2 | %) | (10.6 | %) | |||||||||
| Gross Profit | (8.6 | %) | (9.1 | %) | |||||||||
| Non-GAAP Adjustments(1) | |||||||||||||
| Net Restructuring Charges(3) | 3.8 | 0.4 | |||||||||||
| Adjusted Gross Profit(1) | (6.2 | %) | (6.6 | %) | |||||||||
| Operating (Loss) Income | ( | ) | 100.0 | %* | 100.0 | %* | |||||||
| Non-GAAP Adjustments(1) | |||||||||||||
| Franchise Rights Acquired Impairments | 57.0 | - | |||||||||||
| Net Restructuring Charges(3) | 13.8 | 6.0 | |||||||||||
| Former CEO Separation Expenses | 3.9 | - | |||||||||||
| Adjusted Operating Income(1) | (2.5 | %) | (4.2 | %) | |||||||||
| Net (Loss) Income | ( | ) | 100.0 | %* | 100.0 | %* | |||||||
| EPS | ( | ) | 100.0 | %* | 100.0 | %* | |||||||
| Non-GAAP Adjustments(1) | |||||||||||||
| Franchise Rights Acquired Impairments | 0.65 | - | |||||||||||
| Net Restructuring Charges(3) | 0.13 | 0.06 | |||||||||||
| Former CEO Separation Expenses | 0.04 | - | |||||||||||
| Adjusted EPS(1) | (60.6 | %) | (61.7 | %) | |||||||||
Total Paid Weeks | 48.6 | 52.5 | (7.4 | %) | N/A | ||||||||
| Digital(4) Paid Weeks | 40.4 | 42.8 | (5.6 | %) | N/A | ||||||||
| Workshops + Digital(5) Paid Weeks | 7.2 | 9.1 | (21.2 | %) | N/A | ||||||||
| Clinical(6) Paid Weeks | 1.0 | 0.5 | 91.3 | % | N/A | ||||||||
| End of Period Subscribers(7) | 3.7 | 4.0 | (8.8 | %) | N/A | ||||||||
| Digital Subscribers | 3.0 | 3.3 | (7.3 | %) | N/A | ||||||||
| Workshops + Digital Subscribers | 0.5 | 0.7 | (21.2 | %) | N/A | ||||||||
| Clinical Subscribers | 0.1 | 0.0 | 71.5 | % | N/A | ||||||||
| ___________________________________ Note: Totals may not sum due to rounding. *Note: Percentage in excess of (1) See “Reconciliation of Non-GAAP Financial Measures” attached to this release for further detail on adjustments to GAAP financial measures. (2) “Other Revenues, net” (formerly known as “Product Sales and Other, net”) consist of revenues from licensing and publishing, franchise fees with respect to commitment plans and royalties, and other revenues. Prior to fiscal 2024, “Other Revenues, net” included sales of consumer products. (3) See “Reconciliation of Non-GAAP Financial Measures” attached to this release for further detail on the Company’s previously disclosed 2024, 2023, and 2022 restructuring plans, and the reversal of certain of the charges associated therewith. (4) “Digital” refers to providing subscriptions to the Company’s digital product offerings. (5) “Workshops + Digital” refers to providing subscriptions for unlimited access to the Company’s workshops combined with the Company’s digital subscription product offerings. (6) “Clinical” refers to providing subscriptions to the Company’s clinical product offerings provided by WeightWatchers Clinic (formerly referred to as Sequence) combined with the Company’s digital subscription product offerings. (7) “Subscribers” refers to Digital subscribers, Workshops + Digital subscribers, and Clinical subscribers who participate in recurring bill programs in Company-owned operations. | |||||||||||||
Q3 2024 Business and Financial Highlights
- End of Period Subscribers in Q3 2024 were down
8.8% versus the prior year period, driven by declines in the Digital and Workshops + Digital businesses reflecting year to date recruitment declines. Q3 2024 End of Period Clinical Subscribers of 78 thousand increased71.5% versus the prior year period. - Total Paid Weeks in Q3 2024 were down
7.4% versus the prior year period driven by declines in the Digital and Workshops + Digital businesses. Total Paid Weeks benefited from growth in Clinical Paid Weeks. - Revenues in Q3 2024 were
$192.9 million . On a constant currency basis, Q3 2024 revenues decreased10.6% versus the prior year period.
- Subscription Revenues in Q3 2024 were
$191.2 million . On a constant currency basis, these revenues decreased6.4% versus the prior year period primarily driven by lower recruitments and non-Clinical Incoming Subscribers. Additionally, Subscription Revenues were negatively impacted by the continued mix shift from the Workshops + Digital business to the Digital business and a higher mix of Digital Subscribers within their initial, lower-priced commitment periods. Subscription Revenues benefited from$19.1 million of Clinical Subscription Revenues, which increased90.7% versus the prior year period. - Other Revenues in Q3 2024 were
$1.6 million . On a constant currency basis, these revenues decreased85.7% versus the prior year period driven by the discontinuation of the consumer products business at the end of fiscal 2023.
- Subscription Revenues in Q3 2024 were
- Gross Profit in Q3 2024 was
$129.5 million , compared to$141.8 million in the prior year period. Adjusted gross profit, which excluded the net impact of$3.8 million of restructuring charges, was$133.3 million . Adjusted gross profit in Q3 2023, which excluded the net impact of$0.4 million of restructuring charges, was$142.2 million .
- Gross Margin in Q3 2024 was
67.1% , as compared to66.0% in the prior year period. Adjusted gross margin in Q3 2024 was69.1% , up from an adjusted gross margin of66.2% in the prior year period, driven primarily by actions to reduce the fixed cost base within our business and the discontinuation of our lower margin consumer products business at the end of fiscal 2023.
- Gross Margin in Q3 2024 was
- Non-Cash Intangible Impairment Charges: During Q3 2024, the Company recorded non-cash impairment charges of franchise rights acquired totaling
$57.0 million . These impairments were primarily driven by an increase in the Company’s weighted average cost of capital reflecting market factors. - Operating Loss in Q3 2024 was
$39.0 million , compared to operating income of$30.6 million in the prior year period. Adjusted operating income, which excluded$57.0 million of non-cash intangible impairment charges, the net impact of$13.8 million of restructuring charges, and$3.9 million of former CEO separation expenses, was$35.7 million . Adjusted operating income in Q3 2023, which excluded the net impact of$6.0 million of restructuring charges, was$36.6 million . - Income Tax Benefit in Q3 2024 was
$27.3 million , which reflected the impact of an unusually high negative annual effective tax rate driven by a valuation allowance and small pretax loss reflected in the Company’s full year fiscal 2024 guidance. In the prior year period, income tax benefit was$38.4 million . - Net Loss in Q3 2024 was
$46.2 million compared to net income of$43.7 million in the prior year period. - Diluted Net Loss per share in Q3 2024 was
$0.58 compared to diluted earnings per share of$0.54 in the prior year period. Q3 2024 adjusted earnings per share, which excluded$0.65 of non-cash intangible impairment charges,$0.13 of net impact of restructuring charges, and$0.04 of former CEO separation expenses, was$0.24 . In the prior year period, adjusted earnings per share, which excluded$0.06 of net impact of restructuring charges, was$0.60 .
- Additionally, certain other items affected year-over-year comparability:
- In Q3 2024,
$0.33 per diluted share positive tax impact arising from an unusually high negative annual effective tax rate as a result of a valuation allowance and small pretax loss reflected in the Company’s full year fiscal 2024 guidance. - In Q3 2023,
$0.54 per diluted share positive tax impact arising from an unusually high negative annual effective tax rate as a result of a valuation allowance and small pretax loss reflected in the Company’s full year fiscal 2023 guidance.
- In Q3 2024,
- Additionally, certain other items affected year-over-year comparability:
Other Items
- Cash balance as of September 28, 2024 was
$57.2 million . On that same date, the Company had no outstanding borrowings under its revolving credit facility.
Full Year Fiscal 2024 Guidance
The Company is reiterating its following full year fiscal 2024 guidance:
- Year end total subscribers of at least 3.1 million;
- Revenue of at least
$770.0 million ; and - Excluding non-cash intangible impairment charges and the net impact of restructuring charges (both of which include Q3 2024 charges), and the Q3 2024 former CEO separation expenses,
- Adjusted operating income of at least
$100.0 million ; and - Adjusted EBITDAS of at least
$150.0 million .
- Adjusted operating income of at least
Reflecting the Q3 2024 charges and expenses referred to above, the Company is updating its full year fiscal 2024 operating loss guidance to not exceed
Third Quarter 2024 Conference Call and Webcast
The Company has scheduled a conference call today at 8:30 a.m. ET. During the conference call, Tara Comonte, Interim President and Chief Executive Officer, Heather Stark, Chief Financial Officer, and Donna Boyer, Chief Product Officer, will discuss the third quarter of fiscal 2024 results and answer questions from the investment community.
The live webcast of the conference call will be available on the Company’s corporate website, corporate.ww.com, under Events and Presentations. Supplemental investor materials will also be available in the same location prior to the start of the webcast. A replay of the webcast will be available on this site for approximately 90 days.
Statement regarding Non-GAAP Financial Measures
The following provides information regarding non-GAAP financial measures used in this earnings release and today’s scheduled conference call:
To supplement the Company's consolidated results presented in accordance with accounting principles generally accepted in the United States (“GAAP”), the Company has disclosed non-GAAP financial measures of operating results that exclude or adjust certain items. Gross profit, gross margin, operating (loss) income, operating (loss) income margin, diluted (net loss) earnings per share, and selling, general and administrative expenses are discussed both as reported (on a GAAP basis) and as adjusted (on a non-GAAP basis), as applicable, with respect to (i) the third quarter of fiscal 2024 to exclude (x) the impact of impairment charges for the Company’s franchise rights acquired related to its United States and United Kingdom units of account, (y) the net impact of (a) charges associated with the Company's previously disclosed 2024 restructuring plan (the “2024 plan”), (b) charges associated with the Company's previously disclosed 2023 restructuring plan (the “2023 plan”) or the reversal of certain of the charges associated with the 2023 plan, as applicable and (c) the reversal of certain of the charges associated with the Company's previously disclosed 2022 restructuring plan (the “2022 plan”), and (z) the impact of certain non-recurring expenses in connection with the separation from the Company of its former Chief Executive Officer (“CEO”); (ii) the first nine months of fiscal 2024 to exclude (x) the impact of impairment charges for the Company's franchise rights acquired related to its United States, Australia, United Kingdom and New Zealand units of account, (y) the net impact of charges associated with the 2024 plan, the 2023 plan and the 2022 plan, and (z) the impact of certain non-recurring expenses in connection with the separation of the Company's former CEO; (iii) the third quarter of fiscal 2023 to exclude the net impact of charges associated with the 2023 plan and the reversal of certain of the charges associated with the 2022 plan; and (iv) the first nine months of fiscal 2023 to exclude (x) the net impact of (a) charges associated with the 2023 plan, (b) charges associated with the 2022 plan or the reversal of certain of the charges associated with the 2022 plan, as applicable, (c) charges associated with the Company's previously disclosed 2021 organizational restructuring plan (the “2021 plan”) or the reversal of certain of the charges associated with the 2021 plan, as applicable, and (d) the reversal of certain of the charges associated with the Company's previously disclosed 2020 organizational restructuring plan (the “2020 plan”), and (y) the impact of certain non-recurring transaction costs in connection with the acquisition of Sequence. The Company generally refers to such non-GAAP measures as excluding or adjusting for the impact of franchise rights acquired impairments, the net impact of restructuring charges, the impact of acquisition transaction costs, and the impact of former CEO separation expenses, as applicable. The Company also presents in the attachments to this release the non-GAAP financial measures: earnings before interest, taxes, depreciation, amortization and stock-based compensation (“EBITDAS”); earnings before interest, taxes, depreciation, amortization, stock-based compensation, franchise rights acquired and goodwill impairments, net restructuring charges, acquisition transaction costs and former CEO separation expenses (“Adjusted EBITDAS”); total debt less unamortized deferred financing costs, unamortized debt discount and cash on hand (i.e., net debt); and a net debt/Adjusted EBITDAS ratio. In addition, the Company presents certain of its financial results on a constant currency basis in addition to GAAP results. Constant currency information compares results between periods as if exchange rates had remained constant period-over-period. The Company calculates constant currency by calculating current-year results using prior-year foreign currency exchange rates. A reconciliation of the forward-looking full year EBITDAS outlook to net income cannot be provided without unreasonable effort because of the inherent difficulty of accurately forecasting the occurrence and financial impact of the various adjusting items necessary for such reconciliation that have not yet occurred, are out of the Company's control, or cannot be reasonably predicted. For the same reasons, the Company is unable to assess the probable significance of the unavailable information, which could have a material impact on its future GAAP financial results.
Management believes these non-GAAP financial measures provide useful supplemental information for its and investors' evaluation of the Company's business performance and are useful for period-over-period comparisons of the performance of the Company's business. While management believes that these non-GAAP financial measures are useful in evaluating the Company’s business, this information should be considered as supplemental in nature and is not meant to be considered in isolation or as a substitute for the related financial information prepared in accordance with GAAP. In addition, these non-GAAP financial measures may not be the same as similarly titled measures reported by other companies. See "Reconciliation of Non-GAAP Financial Measures" attached to this release and reconciliations, if any, included elsewhere in this release for a reconciliation of the non-GAAP financial measures to the most directly comparable GAAP measures.
About WW International, Inc.
WeightWatchers is a human-centric technology company powered by our proven, science-based, clinically effective weight loss and weight management programs. For six decades, we have inspired millions of people to adopt healthy habits for real life. We combine technology and community to help members reach and sustain their goals on our programs. To learn more about the WeightWatchers approach to healthy living, please visit ww.com. For more information about our global business, visit our corporate website at corporate.ww.com.
This news release and any attachments include “forward-looking statements,” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, in particular, any guidance and any statements about the Company’s plans, strategies, objectives, initiatives, roadmap and prospects. The Company generally uses the words “may,” “will,” “could,” “expect,” “anticipate,” “believe,” “estimate,” “plan,” “intend,” “aim” and similar expressions in this news release and any attachments to identify forward-looking statements. The Company bases these forward-looking statements on its current views with respect to future events and financial performance. Actual results could differ materially from those projected in the forward-looking statements. These forward-looking statements are subject to risks, uncertainties and assumptions, including, among other things: competition from other weight management and health and wellness industry participants or the development of more effective or more favorably perceived weight management methods; the Company's failure to continue to retain and grow its subscriber base; the Company’s ability to be a leader in the rapidly evolving and increasingly competitive clinical weight management and weight loss market; the Company's ability to continue to develop new, innovative services and products and enhance its existing services and products or the failure of its services, products or brands to continue to appeal to the market, or its ability to successfully expand into new channels of distribution or respond to consumer trends or sentiment; regulatory, reputational and other risks associated with the Company’s new compounded GLP-1 offering; the ability to successfully implement strategic initiatives; the Company’s ability to evolve its community offerings to meet the evolving tastes and preferences of its members; the effectiveness and efficiency of the Company's advertising and marketing programs, including the strength of the Company's social media presence; the impact on the Company's reputation of actions taken by its franchisees, licensees, suppliers, affiliated provider entities, PCs’ healthcare professionals, and other partners, including as a result of its acquisition of Weekend Health, Inc., doing business as Sequence (“Sequence”) (the “Acquisition”); the recognition of asset impairment charges; the loss of key personnel, strategic partners or consultants or failure to effectively manage and motivate the Company's workforce; the Company’s chief executive officer transition, and its ability to appoint a permanent chief executive officer with the required level of experience and expertise; the Company’s ability to successfully make acquisitions or enter into collaborations or joint ventures, including its ability to successfully integrate, operate or realize the anticipated benefits of such businesses, including with respect to Sequence; uncertainties related to a downturn in general economic conditions or consumer confidence, including as a result of the existing inflationary environment, rising interest rates, the potential impact of political and social unrest and increased volatility in the credit and capital markets; the seasonal nature of the Company's business; the Company's failure to maintain effective internal control over financial reporting; the impact of events that impede accessing resources or discourage or impede people from gathering with others; the early termination by the Company of leases; the inability to renew certain of the Company's licenses, or the inability to do so on terms that are favorable to the Company; the impact of the Company's substantial amount of debt, debt service obligations and debt covenants, and its exposure to variable rate indebtedness; the ability to generate sufficient cash to service the Company's debt and satisfy its other liquidity requirements; uncertainties regarding the satisfactory operation of the Company's technology or systems; the impact of data security breaches and other malicious acts or privacy concerns, including the costs of compliance with evolving privacy laws and regulations; the Company’s ability to successfully integrate and use artificial intelligence in its business; the Company's ability to enforce its intellectual property rights both domestically and internationally, as well as the impact of its involvement in any claims related to intellectual property rights; risks and uncertainties associated with the Company's international operations, including regulatory, economic, political, social, intellectual property, and foreign currency risks, which risks may be exacerbated as a result of war and terrorism; the outcomes of litigation or regulatory actions; the impact of existing and future laws and regulations, including federal and state regulations relating to compounded medications; risks related to the Acquisition, including risks that the Acquisition may not achieve its intended results; risks related to the Company's exposure to extensive and complex healthcare laws and regulations as a result of the Acquisition; and other risks and uncertainties, including those detailed from time to time in the Company's periodic reports filed with the United States Securities and Exchange Commission (the “SEC”) (which are available on the SEC’s EDGAR database at www.sec.gov and via the Company’s website at corporate.ww.com). You should not put undue reliance on any forward-looking statements. You should understand that many important factors, including those discussed herein, could cause the Company’s results to differ materially from those expressed or suggested in any forward-looking statement. Except as required by law, the Company does not undertake any obligation to update or revise these forward-looking statements to reflect new information or events or circumstances that occur after the date of this news release or to reflect the occurrence of unanticipated events or otherwise. Readers are advised to review the Company’s filings with the SEC (which are available on the SEC’s EDGAR database at www.sec.gov and via the Company’s website at corporate.ww.com).
For more information, contact:
Investors:
John Mills or Anna Kate Heller
WeightWatchers@icrinc.com
Media:
Kelsey Merkel
Communications@ww.com
| WW INTERNATIONAL, INC. AND SUBSIDIARIES | |||||||||
| CONSOLIDATED BALANCE SHEETS AT | |||||||||
| (IN THOUSANDS) | |||||||||
| UNAUDITED | |||||||||
| September 28, | December 30, | ||||||||
| 2024 | 2023 | ||||||||
| ASSETS | |||||||||
| CURRENT ASSETS | |||||||||
| Cash and cash equivalents | $ | 57,181 | $ | 109,366 | |||||
| Receivables (net of allowances: September 28, 2024 - | 12,615 | 14,938 | |||||||
| Prepaid income taxes | 11,240 | 25,370 | |||||||
| Prepaid marketing and advertising | 3,390 | 10,149 | |||||||
| Prepaid expenses and other current assets | 16,802 | 19,651 | |||||||
| TOTAL CURRENT ASSETS | 101,228 | 179,474 | |||||||
| Property and equipment, net | 16,901 | 19,741 | |||||||
| Operating lease assets | 45,312 | 52,272 | |||||||
| Franchise rights acquired | 71,184 | 386,526 | |||||||
| Goodwill | 242,754 | 243,441 | |||||||
| Other intangible assets, net | 49,319 | 63,208 | |||||||
| Deferred income taxes | 17,309 | 19,683 | |||||||
| Other noncurrent assets | 18,346 | 17,685 | |||||||
| TOTAL ASSETS | $ | 562,353 | $ | 982,030 | |||||
| LIABILITIES AND TOTAL DEFICIT | |||||||||
| CURRENT LIABILITIES | |||||||||
| Portion of operating lease liabilities due within one year | $ | 8,976 | $ | 9,613 | |||||
| Accounts payable | 16,739 | 18,507 | |||||||
| Salaries and wages payable | 62,253 | 79,096 | |||||||
| Accrued marketing and advertising | 11,519 | 18,215 | |||||||
| Accrued interest | 17,478 | 5,346 | |||||||
| Deferred acquisition payable | 15,055 | 16,500 | |||||||
| Other accrued liabilities | 19,307 | 22,610 | |||||||
| Income taxes payable | 6,705 | 1,609 | |||||||
| Deferred revenue | 31,425 | 33,966 | |||||||
| TOTAL CURRENT LIABILITIES | 189,457 | 205,462 | |||||||
| Long-term debt, net | 1,429,598 | 1,426,464 | |||||||
| Long-term operating lease liabilities | 46,925 | 53,461 | |||||||
| Deferred income taxes | 23,467 | 41,994 | |||||||
| Other | 1,626 | 15,743 | |||||||
| TOTAL LIABILITIES | 1,691,073 | 1,743,124 | |||||||
| TOTAL DEFICIT | |||||||||
| Common stock, | 0 | 0 | |||||||
| Treasury stock, at cost, 50,314 shares at September 28, 2024 and 50,859 shares at December 30, 2023 | (3,039,309 | ) | (3,064,628 | ) | |||||
| Retained earnings | 1,925,146 | 2,314,834 | |||||||
| Accumulated other comprehensive loss | (14,557 | ) | (11,300 | ) | |||||
| TOTAL DEFICIT | (1,128,720 | ) | (761,094 | ) | |||||
| TOTAL LIABILITIES AND TOTAL DEFICIT | $ | 562,353 | $ | 982,030 | |||||
| WW INTERNATIONAL, INC. AND SUBSIDIARIES | ||||||||||
| CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||||
| (IN THOUSANDS, EXCEPT PER SHARE AMOUNTS) | ||||||||||
| UNAUDITED | ||||||||||
| Three Months Ended | ||||||||||
| September 28, | September 30, | |||||||||
| 2024 | 2023 | |||||||||
| Subscription revenues, net (1) | $ | 191,248 | $ | 203,496 | ||||||
| Other revenues, net (2) | 1,639 | 11,375 | ||||||||
| Revenues, net | 192,887 | 214,871 | ||||||||
| Cost of subscription revenues (3) | 63,329 | 67,080 | ||||||||
| Cost of other revenues | 62 | 6,036 | ||||||||
| Cost of revenues | 63,391 | 73,116 | ||||||||
| Gross profit | 129,496 | 141,755 | ||||||||
| Marketing expenses | 44,402 | 48,114 | ||||||||
| Selling, general and administrative expenses | 67,094 | 63,034 | ||||||||
| Franchise rights acquired impairments | 57,045 | — | ||||||||
| Operating (loss) income | (39,045 | ) | 30,607 | |||||||
| Interest expense | 28,619 | 24,508 | ||||||||
| Other expense, net | 5,870 | 815 | ||||||||
| (Loss) income before income taxes | (73,534 | ) | 5,284 | |||||||
| Benefit from income taxes | (27,342 | ) | (38,447 | ) | ||||||
| Net (loss) income | $ | (46,192 | ) | $ | 43,731 | |||||
| (Net loss) earnings per share | ||||||||||
| Basic | $ | (0.58 | ) | $ | 0.55 | |||||
| Diluted | $ | (0.58 | ) | $ | 0.54 | |||||
| Weighted average common shares outstanding | ||||||||||
| Basic | 79,732 | 78,979 | ||||||||
| Diluted | 79,732 | 80,638 | ||||||||
| ____ | ||||||||||
| Note: Totals may not sum due to rounding. | ||||||||||
| (1) “Subscription revenues, net” consist of net “Digital Subscription Revenues”, net “Workshops + Digital Subscription Revenues” and net “Clinical Subscription Revenues”. “Digital Subscription Revenues” consist of the fees associated with subscriptions for the Company’s Digital offerings. “Workshops + Digital Subscription Revenues” consist of the fees associated with subscriptions for combined workshops and Digital offerings. “Clinical Subscription Revenues” consist of the fees associated with subscriptions for combined Clinical and Digital offerings. | ||||||||||
| (2) “Other revenues, net” (formerly known as “product sales and other, net”) consist of revenues from licensing and publishing, franchise fees with respect to commitment plans and royalties, and other revenues. Prior to fiscal 2024, “Other revenues, net” included sales of consumer products. | ||||||||||
| (3) “Cost of subscription revenues” consists of cost of revenues and operating expenses for the Company's Digital, Workshops + Digital and Clinical services. | ||||||||||
| WW INTERNATIONAL, INC. AND SUBSIDIARIES | ||||||||||
| CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||||
| (IN THOUSANDS, EXCEPT PER SHARE AMOUNTS) | ||||||||||
| UNAUDITED | ||||||||||
| Nine Months Ended | ||||||||||
| September 28, | September 30, | |||||||||
| 2024 | 2023 | |||||||||
| Subscription revenues, net (1) | $ | 595,260 | $ | 626,667 | ||||||
| Other revenues, net (2) | 6,248 | 56,927 | ||||||||
| Revenues, net | 601,508 | 683,594 | ||||||||
| Cost of subscription revenues (3) | 195,168 | 233,354 | ||||||||
| Cost of other revenues | 1,750 | 45,794 | ||||||||
| Cost of revenues | 196,918 | 279,148 | ||||||||
| Gross profit | 404,590 | 404,446 | ||||||||
| Marketing expenses | 188,260 | 187,468 | ||||||||
| Selling, general and administrative expenses | 173,741 | 188,638 | ||||||||
| Franchise rights acquired impairments | 315,033 | — | ||||||||
| Operating (loss) income | (272,444 | ) | 28,340 | |||||||
| Interest expense | 81,923 | 71,429 | ||||||||
| Other expense (income), net | 4,187 | (36 | ) | |||||||
| Loss before income taxes | (358,554 | ) | (43,053 | ) | ||||||
| Provision for (benefit from) income taxes | 12,270 | (18,933 | ) | |||||||
| Net loss | $ | (370,824 | ) | $ | (24,120 | ) | ||||
| Net loss per share | ||||||||||
| Basic | $ | (4.67 | ) | $ | (0.32 | ) | ||||
| Diluted | $ | (4.67 | ) | $ | (0.32 | ) | ||||
| Weighted average common shares outstanding | ||||||||||
| Basic | 79,474 | 75,861 | ||||||||
| Diluted | 79,474 | 75,861 | ||||||||
| ____ | ||||||||||
| Note: Totals may not sum due to rounding. | ||||||||||
| (1) “Subscription revenues, net” consist of net “Digital Subscription Revenues”, net “Workshops + Digital Subscription Revenues” and net “Clinical Subscription Revenues”. “Digital Subscription Revenues” consist of the fees associated with subscriptions for the Company’s Digital offerings. “Workshops + Digital Subscription Revenues” consist of the fees associated with subscriptions for combined workshops and Digital offerings. “Clinical Subscription Revenues” consist of the fees associated with subscriptions for combined Clinical and Digital offerings. | ||||||||||
| (2) “Other revenues, net” (formerly known as “product sales and other, net”) consist of revenues from licensing and publishing, franchise fees with respect to commitment plans and royalties, and other revenues. Prior to fiscal 2024, “Other revenues, net” included sales of consumer products. | ||||||||||
| (3) “Cost of subscription revenues” consists of cost of revenues and operating expenses for the Company's Digital, Workshops + Digital and Clinical services. | ||||||||||
| WW INTERNATIONAL, INC. AND SUBSIDIARIES | |||||||||
| CONSOLIDATED STATEMENTS OF CASH FLOWS | |||||||||
| (IN THOUSANDS) | |||||||||
| UNAUDITED | |||||||||
| Nine Months Ended | |||||||||
| September 28, | September 30, | ||||||||
| 2024 | 2023 | ||||||||
| Operating activities: | |||||||||
| Net loss | $ | (370,824 | ) | $ | (24,120 | ) | |||
| Adjustments to reconcile net loss to cash used for operating activities: | |||||||||
| Depreciation and amortization | 29,103 | 39,805 | |||||||
| Amortization of deferred financing costs and debt discount | 3,763 | 3,763 | |||||||
| Impairment of franchise rights acquired | 315,033 | — | |||||||
| Impairment of intangible and long-lived assets | 297 | 197 | |||||||
| Share-based compensation expense | 7,059 | 12,838 | |||||||
| Deferred tax benefit | (15,905 | ) | (7,449 | ) | |||||
| Allowance for doubtful accounts | 12,296 | 407 | |||||||
| Reserve for inventory obsolescence | 75 | 1,897 | |||||||
| Foreign currency exchange rate loss (gain) | 1,902 | (31 | ) | ||||||
| Changes in cash due to: | |||||||||
| Receivables | 4,675 | 9,117 | |||||||
| Inventories | 97 | 9,009 | |||||||
| Prepaid expenses | 19,754 | (27,301 | ) | ||||||
| Accounts payable | (1,718 | ) | 1,221 | ||||||
| Accrued liabilities | (14,551 | ) | (17,010 | ) | |||||
| Deferred revenue | (2,745 | ) | 309 | ||||||
| Other long term assets and liabilities, net | (15,334 | ) | (2,701 | ) | |||||
| Income taxes | 5,576 | (1,104 | ) | ||||||
| Cash used for operating activities | (21,447 | ) | (1,153 | ) | |||||
| Investing activities: | |||||||||
| Capital expenditures | (598 | ) | (2,143 | ) | |||||
| Capitalized software and website development expenditures | (12,620 | ) | (26,190 | ) | |||||
| Cash paid for acquisitions, net of cash acquired | — | (38,362 | ) | ||||||
| Other items, net | (5 | ) | (14 | ) | |||||
| Cash used for investing activities | (13,223 | ) | (66,709 | ) | |||||
| Financing activities: | |||||||||
| Taxes paid related to net share settlement of equity awards | (631 | ) | (1,417 | ) | |||||
| Proceeds from stock options exercised | — | 710 | |||||||
| Cash paid for acquisitions | (16,500 | ) | (1,178 | ) | |||||
| Other items, net | (4 | ) | (43 | ) | |||||
| Cash used for financing activities | (17,135 | ) | (1,928 | ) | |||||
| Effect of exchange rate changes on cash and cash equivalents | (380 | ) | (1,038 | ) | |||||
| Net decrease in cash and cash equivalents | (52,185 | ) | (70,828 | ) | |||||
| Cash and cash equivalents, beginning of period | 109,366 | 178,326 | |||||||
| Cash and cash equivalents, end of period | $ | 57,181 | $ | 107,498 | |||||
| WW INTERNATIONAL, INC. AND SUBSIDIARIES | |||||||
| OPERATIONAL STATISTICS | |||||||
| (IN THOUSANDS, EXCEPT PERCENTAGES) | |||||||
| UNAUDITED | |||||||
| Three Months Ended | |||||||
| September 28, | September 30, | ||||||
| 2024 | 2023 | Variance | |||||
| Paid Weeks (1) | |||||||
| Digital Paid Weeks | 40,397 | 42,810 | (5.6 | %) | |||
| Workshops + Digital Paid Weeks | 7,202 | 9,133 | (21.2 | %) | |||
| Clinical Paid Weeks | 1,022 | 534 | 91.3 | % | |||
| Total Paid Weeks | 48,621 | 52,478 | (7.4 | %) | |||
| End of Period Subscribers (2) | |||||||
| End of Period Digital Subscribers | 3,043 | 3,284 | (7.3 | %) | |||
| End of Period Workshops + Digital Subscribers | 546 | 693 | (21.2 | %) | |||
| End of Period Clinical Subscribers | 78 | 45 | 71.5 | % | |||
| Total End of Period Subscribers | 3,667 | 4,022 | (8.8 | %) | |||
| ____ | |||||||
| Note: Totals may not sum due to rounding. | |||||||
| (1) The “Paid Weeks” metric reports paid weeks by WW customers in Company-owned operations for a given period as follows: (i) “Digital Paid Weeks” is the total paid subscription weeks for the Company’s Digital offerings; (ii) “Workshops + Digital Paid Weeks” is the total paid subscription weeks for combined workshops and Digital offerings; (iii) “Clinical Paid Weeks” is the total paid subscription weeks for combined Clinical and Digital offerings; and (iv) “Total Paid Weeks” is the sum of Digital Paid Weeks, Workshops + Digital Paid Weeks and Clinical Paid Weeks. | |||||||
| (2) The “End of Period Subscribers” metric reports WW subscribers in Company-owned operations at a given period end as follows: (i) “End of Period Digital Subscribers” is the total number of Digital subscribers; (ii) “End of Period Workshops + Digital Subscribers” is the total number of subscribers that have access to combined workshops and Digital offerings; (iii) “End of Period Clinical Subscribers” is the total number of subscribers that have access to combined Clinical and Digital offerings; and (iv) “End of Period Subscribers” is the sum of End of Period Digital Subscribers, End of Period Workshops + Digital Subscribers and End of Period Clinical Subscribers. | |||||||
| WW INTERNATIONAL, INC. AND SUBSIDIARIES | |||||||
| OPERATIONAL STATISTICS | |||||||
| (IN THOUSANDS, EXCEPT PERCENTAGES) | |||||||
| UNAUDITED | |||||||
| Nine Months Ended | |||||||
| September 28, | September 30, | ||||||
| 2024 | 2023 | Variance | |||||
| Paid Weeks (1) | |||||||
| Digital Paid Weeks | 124,695 | 126,858 | (1.7 | %) | |||
| Workshops + Digital Paid Weeks | 23,308 | 29,039 | (19.7 | %) | |||
| Clinical Paid Weeks | 3,144 | 889 | 253.6 | % | |||
| Total Paid Weeks | 151,147 | 156,786 | (3.6 | %) | |||
| End of Period Subscribers (2) | |||||||
| End of Period Digital Subscribers | 3,043 | 3,284 | (7.3 | %) | |||
| End of Period Workshops + Digital Subscribers | 546 | 693 | (21.2 | %) | |||
| End of Period Clinical Subscribers | 78 | 45 | 71.5 | % | |||
| Total End of Period Subscribers | 3,667 | 4,022 | (8.8 | %) | |||
| ____ | |||||||
| Note: Totals may not sum due to rounding. | |||||||
| (1) The “Paid Weeks” metric reports paid weeks by WW customers in Company-owned operations for a given period as follows: (i) “Digital Paid Weeks” is the total paid subscription weeks for the Company’s Digital offerings; (ii) “Workshops + Digital Paid Weeks” is the total paid subscription weeks for combined workshops and Digital offerings; (iii) “Clinical Paid Weeks” is the total paid subscription weeks for combined Clinical and Digital offerings; and (iv) “Total Paid Weeks” is the sum of Digital Paid Weeks, Workshops + Digital Paid Weeks and Clinical Paid Weeks. | |||||||
| (2) The “End of Period Subscribers” metric reports WW subscribers in Company-owned operations at a given period end as follows: (i) “End of Period Digital Subscribers” is the total number of Digital subscribers; (ii) “End of Period Workshops + Digital Subscribers” is the total number of subscribers that have access to combined workshops and Digital offerings; (iii) “End of Period Clinical Subscribers” is the total number of subscribers that have access to combined Clinical and Digital offerings; and (iv) “End of Period Subscribers” is the sum of End of Period Digital Subscribers, End of Period Workshops + Digital Subscribers and End of Period Clinical Subscribers. | |||||||
| WW INTERNATIONAL, INC. AND SUBSIDIARIES | ||||||||||||||||||
| RECONCILIATION OF NON-GAAP FINANCIAL MEASURES | ||||||||||||||||||
| (IN THOUSANDS, EXCEPT PERCENTAGES) | ||||||||||||||||||
| UNAUDITED | ||||||||||||||||||
| Q3 2024 Variance | ||||||||||||||||||
| 2024 | ||||||||||||||||||
| Constant | ||||||||||||||||||
| Q3 2024 | Q3 2023 | 2024 | Currency | |||||||||||||||
| Currency | Constant | vs | vs | |||||||||||||||
| GAAP | Adjustment | Currency | GAAP | 2023 | 2023 | |||||||||||||
| Selected Financial Data | ||||||||||||||||||
| Total Revenues | $ | 192,887 | $ | (710 | ) | $ | 192,177 | $ | 214,871 | (10.2 | %) | (10.6 | %) | |||||
| Digital Subscription Revenues (1) | $ | 127,179 | $ | (571 | ) | $ | 126,608 | $ | 140,889 | (9.7 | %) | (10.1 | %) | |||||
| Workshops + Digital Subscription Revenues (2) | $ | 45,015 | $ | (121 | ) | $ | 44,894 | $ | 52,618 | (14.4 | %) | (14.7 | %) | |||||
| Clinical Subscription Revenues (3) | $ | 19,054 | $ | — | $ | 19,054 | $ | 9,989 | 90.7 | % | 90.7 | % | ||||||
| Subscription Revenues (4) | $ | 191,248 | $ | (693 | ) | $ | 190,555 | $ | 203,496 | (6.0 | %) | (6.4 | %) | |||||
| Other Revenues (5) | $ | 1,639 | $ | (17 | ) | $ | 1,622 | $ | 11,375 | (85.6 | %) | (85.7 | %) | |||||
| ____ | ||||||||||||||||||
| Note: Totals may not sum due to rounding. | ||||||||||||||||||
| (1) “Digital Subscription Revenues” consist of the fees associated with subscriptions for the Company’s Digital offerings. | ||||||||||||||||||
| (2) “Workshops + Digital Subscription Revenues” consist of the fees associated with subscriptions for combined workshops and Digital offerings. | ||||||||||||||||||
| (3) “Clinical Subscription Revenues” consist of the fees associated with subscriptions for combined Clinical and Digital offerings. | ||||||||||||||||||
| (4) “Subscription Revenues” equal “Digital Subscription Revenues” plus “Workshops + Digital Subscription Revenues” plus “Clinical Subscription Revenues”. | ||||||||||||||||||
| (5) “Other Revenues” (formerly known as “product sales and other”) consist of revenues from licensing and publishing, franchise fees with respect to commitment plans and royalties, and other revenues. Prior to fiscal 2024, “Other Revenues” included sales of consumer products. | ||||||||||||||||||
| WW INTERNATIONAL, INC. AND SUBSIDIARIES | ||||||||||||||||||
| RECONCILIATION OF NON-GAAP FINANCIAL MEASURES | ||||||||||||||||||
| (IN THOUSANDS, EXCEPT PERCENTAGES) | ||||||||||||||||||
| UNAUDITED | ||||||||||||||||||
| YTD 2024 Variance | ||||||||||||||||||
| 2024 | ||||||||||||||||||
| Constant | ||||||||||||||||||
| YTD 2024 | YTD 2023 | 2024 | Currency | |||||||||||||||
| Currency | Constant | vs | vs | |||||||||||||||
| GAAP | Adjustment | Currency | GAAP | 2023 | 2023 | |||||||||||||
| Selected Financial Data | ||||||||||||||||||
| Total Revenues | $ | 601,508 | $ | (840 | ) | $ | 600,668 | $ | 683,594 | (12.0 | %) | (12.1 | %) | |||||
| Digital Subscription Revenues (1) | $ | 399,364 | $ | (614 | ) | $ | 398,750 | $ | 437,613 | (8.7 | %) | (8.9 | %) | |||||
| Workshops + Digital Subscription Revenues (2) | $ | 138,367 | $ | (206 | ) | $ | 138,161 | $ | 171,473 | (19.3 | %) | (19.4 | %) | |||||
| Clinical Subscription Revenues (3) | $ | 57,529 | $ | — | $ | 57,529 | $ | 17,581 | 227.2 | % | 227.2 | % | ||||||
| Subscription Revenues (4) | $ | 595,260 | $ | (820 | ) | $ | 594,440 | $ | 626,667 | (5.0 | %) | (5.1 | %) | |||||
| Other Revenues (5) | $ | 6,248 | $ | (20 | ) | $ | 6,228 | $ | 56,927 | (89.0 | %) | (89.1 | %) | |||||
| ____ | ||||||||||||||||||
| Note: Totals may not sum due to rounding. | ||||||||||||||||||
| (1) “Digital Subscription Revenues” consist of the fees associated with subscriptions for the Company’s Digital offerings. | ||||||||||||||||||
| (2) “Workshops + Digital Subscription Revenues” consist of the fees associated with subscriptions for combined workshops and Digital offerings. | ||||||||||||||||||
| (3) “Clinical Subscription Revenues” consist of the fees associated with subscriptions for combined Clinical and Digital offerings. | ||||||||||||||||||
| (4) “Subscription Revenues” equal “Digital Subscription Revenues” plus “Workshops + Digital Subscription Revenues” plus “Clinical Subscription Revenues”. | ||||||||||||||||||
| (5) “Other Revenues” (formerly known as “product sales and other”) consist of revenues from licensing and publishing, franchise fees with respect to commitment plans and royalties, and other revenues. Prior to fiscal 2024, “Other Revenues” included sales of consumer products. | ||||||||||||||||||
| WW INTERNATIONAL, INC. AND SUBSIDIARIES | |||||||||||||||||||||||||||||||||||||||||
| RECONCILIATION OF NON-GAAP FINANCIAL MEASURES | |||||||||||||||||||||||||||||||||||||||||
| (IN THOUSANDS, EXCEPT PERCENTAGES AND PER SHARE AMOUNTS) | |||||||||||||||||||||||||||||||||||||||||
| UNAUDITED | |||||||||||||||||||||||||||||||||||||||||
| Q3 2024 Variance | |||||||||||||||||||||||||||||||||||||||||
| 2024 Constant Currency | |||||||||||||||||||||||||||||||||||||||||
| 2024 | 2024 | ||||||||||||||||||||||||||||||||||||||||
| Q3 2024 | Q3 2023 | Adjusted | Adjusted | ||||||||||||||||||||||||||||||||||||||
| Adjusted | 2024 | vs | 2024 | vs | |||||||||||||||||||||||||||||||||||||
| Currency | Constant | Constant | vs | 2023 | vs | 2023 | |||||||||||||||||||||||||||||||||||
| GAAP | Adjustment | Adjusted | Adjustment | Currency | Currency | GAAP | Adjustment | Adjusted | 2023 | Adjusted | 2023 | Adjusted | |||||||||||||||||||||||||||||
| Selected Financial Data | |||||||||||||||||||||||||||||||||||||||||
| Gross Profit | $ | 129,496 | $ | 3,820 | (1) | $ | 133,316 | $ | (598) | $ | 128,898 | $ | 132,718 | $ | 141,755 | $ | 398 | (11) | $ | 142,153 | ( | ( | ( | ( | |||||||||||||||||
| Gross Margin | |||||||||||||||||||||||||||||||||||||||||
| Selling, General and Administrative Expenses | $ | 67,094 | $ | (13,844) | (2) | $ | 53,250 | $ | (63) | $ | 67,031 | $ | 53,186 | $ | 63,034 | $ | (5,577) | (12) | $ | 57,457 | ( | ( | |||||||||||||||||||
| Operating (Loss) Income | $ | (39,045) | $ | 74,709 | (3) | $ | 35,664 | $ | (457) | $ | (39,502) | $ | 35,033 | (7) | $ | 30,607 | $ | 5,975 | (13) | $ | 36,582 | ( | ( | ( | ( | ||||||||||||||||
| Operating (Loss) Income Margin | ( | ( | |||||||||||||||||||||||||||||||||||||||
| Benefit from Income Taxes | $ | (27,342) | $ | 9,694 | (4) | $ | (17,648) | $ | (118) | $ | (27,460) | $ | (17,789) | (8) | $ | (38,447) | $ | 1,496 | (14) | $ | (36,951) | ( | ( | ( | ( | ||||||||||||||||
| Net (Loss) Income | $ | (46,192) | $ | 65,015 | (5) | $ | 18,823 | $ | (339) | $ | (46,531) | $ | 18,333 | (9) | $ | 43,731 | $ | 4,479 | (15) | $ | 48,210 | ( | ( | ( | ( | ||||||||||||||||
| Diluted (Net Loss) Earnings Per Share | $ | (0.58) | $ | 0.82 | (6) | $ | 0.24 | $ | (0.00) | $ | (0.58) | $ | 0.23 | (10) | $ | 0.54 | $ | 0.06 | (16) | $ | 0.60 | ( | ( | ( | ( | ||||||||||||||||
| ____ | |||||||||||||||||||||||||||||||||||||||||
| Note: Totals may not sum due to rounding. | |||||||||||||||||||||||||||||||||||||||||
| (1) Excludes the net impact of | |||||||||||||||||||||||||||||||||||||||||
| (2) Excludes the net impact of | |||||||||||||||||||||||||||||||||||||||||
| (3) Excludes (i) the impact of impairment charges of the Company's franchise rights acquired of | |||||||||||||||||||||||||||||||||||||||||
| (4) Excludes (i) the impact of impairment charges of the Company's franchise rights acquired of | |||||||||||||||||||||||||||||||||||||||||
| (5) Excludes (i) the impact of impairment charges of the Company's franchise rights acquired of | |||||||||||||||||||||||||||||||||||||||||
| (6) Excludes (i) the impact of impairment charges of the Company's franchise rights acquired of | |||||||||||||||||||||||||||||||||||||||||
| (7) Includes | |||||||||||||||||||||||||||||||||||||||||
| (8) Includes | |||||||||||||||||||||||||||||||||||||||||
| (9) Includes | |||||||||||||||||||||||||||||||||||||||||
| (10) Includes | |||||||||||||||||||||||||||||||||||||||||
| (11) Excludes the net impact of | |||||||||||||||||||||||||||||||||||||||||
| (12) Excludes the net impact of | |||||||||||||||||||||||||||||||||||||||||
| (13) Excludes the net impact of (a) | |||||||||||||||||||||||||||||||||||||||||
| (14) Excludes the net impact of | |||||||||||||||||||||||||||||||||||||||||
| (15) Excludes the net impact of | |||||||||||||||||||||||||||||||||||||||||
| (16) Excludes the net impact of | |||||||||||||||||||||||||||||||||||||||||
| WW INTERNATIONAL, INC. AND SUBSIDIARIES | ||||||||||||||||||||||||||||||||||
| RECONCILIATION OF NON-GAAP FINANCIAL MEASURES | ||||||||||||||||||||||||||||||||||
| (IN THOUSANDS, EXCEPT PERCENTAGES AND PER SHARE AMOUNTS) | ||||||||||||||||||||||||||||||||||
| UNAUDITED | ||||||||||||||||||||||||||||||||||
| YTD 2024 Variance | ||||||||||||||||||||||||||||||||||
| 2024 Constant Currency | ||||||||||||||||||||||||||||||||||
| 2024 | 2024 | |||||||||||||||||||||||||||||||||
| YTD 2024 | YTD 2023 | Adjusted | Adjusted | |||||||||||||||||||||||||||||||
| Adjusted | 2024 | vs | 2024 | vs | ||||||||||||||||||||||||||||||
| Currency | Constant | Constant | vs | 2023 | vs | 2023 | ||||||||||||||||||||||||||||
| GAAP | Adjustment | Adjusted | Adjustment | Currency | Currency | GAAP | Adjustment | Adjusted | 2023 | Adjusted | 2023 | Adjusted | ||||||||||||||||||||||
| Selected Financial Data | ||||||||||||||||||||||||||||||||||
| Gross Profit | $ | 404,590 | $ | 6,173 | (1) | $ | 410,763 | $ | (668) | $ | 403,922 | $ | 410,095 | $ | 404,446 | $ | 19,675 | (10) | $ | 424,121 | ( | ( | ( | |||||||||||
| Gross Margin | 67.3% | 68.3% | 67.2% | 68.3% | 59.2% | 62.0% | ||||||||||||||||||||||||||||
| Selling, General and Administrative Expenses | $ | 173,741 | $ | (19,207) | (2) | $ | 154,534 | $ | (120) | $ | 173,621 | $ | 154,414 | $ | 188,638 | $ | (20,215) | (11) | $ | 168,423 | ( | ( | ( | ( | ||||||||||
| Operating (Loss) Income | $ | (272,444) | $ | 340,413 | (3) | $ | 67,969 | $ | (439) | $ | (272,883) | $ | 67,461 | (7) | $ | 28,340 | $ | 39,890 | (12) | $ | 68,230 | (1, | ( | (1, | ( | |||||||||
| Operating (Loss) Income Margin | (45.3%) | 11.3% | (45.4%) | 11.2% | 4.1% | 10.0% | ||||||||||||||||||||||||||||
| Provision for (Benefit from) Income Taxes | $ | 12,270 | $ | 28,127 | (4) | $ | 40,397 | $ | (111) | $ | 12,159 | $ | 40,280 | (8) | $ | (18,933) | $ | 8,904 | (13) | $ | (10,029) | ( | ( | ( | ( | |||||||||
| Net Loss | $ | (370,824) | $ | 312,286 | (5) | $ | (58,538) | $ | (327) | $ | (371,151) | $ | (58,928) | (9) | $ | (24,120) | $ | 30,986 | (14) | $ | 6,866 | 1, | ( | 1, | ( | |||||||||
| Diluted Net Loss Per Share | $ | (4.67) | $ | 3.93 | (6) | $ | (0.74) | $ | (0.00) | $ | (4.67) | $ | (0.74) | $ | (0.32) | $ | 0.41 | (15) | $ | 0.09 | 1, | ( | 1, | ( | ||||||||||
| ____ | ||||||||||||||||||||||||||||||||||
| Note: Totals may not sum due to rounding. | ||||||||||||||||||||||||||||||||||
| (1) Excludes the net impact of | ||||||||||||||||||||||||||||||||||
| (2) Excludes the net impact of | ||||||||||||||||||||||||||||||||||
| (3) Excludes (i) the impact of impairment charges of the Company's franchise rights acquired of | ||||||||||||||||||||||||||||||||||
| (4) Excludes (i) the impact of impairment charges of the Company's franchise rights acquired of | ||||||||||||||||||||||||||||||||||
| (5) Excludes (i) the impact of impairment charges of the Company's franchise rights acquired of | ||||||||||||||||||||||||||||||||||
| (6) Excludes (i) the impact of impairment charges of the Company's franchise rights acquired of | ||||||||||||||||||||||||||||||||||
| (7) Includes | ||||||||||||||||||||||||||||||||||
| (8) Includes | ||||||||||||||||||||||||||||||||||
| (9) Includes | ||||||||||||||||||||||||||||||||||
| (10) Excludes the net impact of | ||||||||||||||||||||||||||||||||||
| (11) Excludes (i) the net impact of | ||||||||||||||||||||||||||||||||||
| (12) Excludes (i) the net impact of (a) | ||||||||||||||||||||||||||||||||||
| (13) Excludes (i) the net impact of | ||||||||||||||||||||||||||||||||||
| (14) Excludes (i) the net impact of | ||||||||||||||||||||||||||||||||||
| (15) Excludes (i) the net impact of | ||||||||||||||||||||||||||||||||||
| WW INTERNATIONAL, INC. AND SUBSIDIARIES | ||||||||||||||||
| RECONCILIATION OF NON-GAAP FINANCIAL MEASURES | ||||||||||||||||
| (IN THOUSANDS) | ||||||||||||||||
| UNAUDITED | ||||||||||||||||
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 28, | September 30, | September 28, | September 30, | |||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
| Net (Loss) Income | $ | (46,192 | ) | $ | 43,731 | $ | (370,824 | ) | $ | (24,120 | ) | |||||
| Interest | 28,619 | 24,508 | 81,923 | 71,429 | ||||||||||||
| Taxes | (27,342 | ) | (38,447 | ) | 12,270 | (18,933 | ) | |||||||||
| Depreciation and Amortization | 9,155 | 13,428 | 29,103 | 35,633 | ||||||||||||
| Stock-based Compensation | 824 | 3,225 | 5,966 | 8,956 | ||||||||||||
| EBITDAS | $ | (34,936 | ) | $ | 46,445 | $ | (241,562 | ) | $ | 72,965 | ||||||
| Franchise Rights Acquired Impairments | 57,045 | (1) | — | 315,033 | (2) | — | ||||||||||
| 2024 Plan Restructuring Charges (3) | 14,812 | — | 14,812 | — | ||||||||||||
| 2023 Plan Restructuring Charges (4) | (749 | ) | 6,187 | 6,654 | 30,603 | |||||||||||
| 2022 Plan Restructuring Charges (5) | (257 | ) | (212 | ) | 56 | 646 | ||||||||||
| 2021 Plan Restructuring Charges (6) | — | — | — | 57 | ||||||||||||
| 2020 Plan Restructuring Charges (7) | — | — | — | (21 | ) | |||||||||||
| Acquisition Transaction Costs (8) | — | — | — | 8,605 | ||||||||||||
| Former CEO Separation Expenses (9) | 3,858 | — | 3,858 | — | ||||||||||||
| Adjusted EBITDAS | $ | 39,773 | $ | 52,420 | $ | 98,851 | $ | 112,855 | ||||||||
| ____ | ||||||||||||||||
| Note: Totals may not sum due to rounding. | ||||||||||||||||
| (1) Impairment charges of the Company's franchise rights acquired of | ||||||||||||||||
| (2) Impairment charges of the Company's franchise rights acquired of | ||||||||||||||||
| (3) Charges associated with the Company's previously disclosed 2024 restructuring plan. | ||||||||||||||||
| (4) The reversal of charges or charges, as applicable, associated with the Company's previously disclosed 2023 restructuring plan. | ||||||||||||||||
| (5) The reversal of charges or charges, as applicable, associated with the Company's previously disclosed 2022 restructuring plan. | ||||||||||||||||
| (6) Charges associated with the Company's previously disclosed 2021 organizational restructuring plan. | ||||||||||||||||
| (7) The reversal of charges associated with the Company's previously disclosed 2020 organizational restructuring plan. | ||||||||||||||||
| (8) Certain non-recurring transaction costs in connection with the Company's acquisition of Sequence. | ||||||||||||||||
| (9) Certain non-recurring expenses in connection with the separation from the Company of its former Chief Executive Officer. | ||||||||||||||||
| WW INTERNATIONAL, INC. AND SUBSIDIARIES | |||||||||||||||||||||
| RECONCILIATION OF NON-GAAP FINANCIAL MEASURES | |||||||||||||||||||||
| (IN THOUSANDS, EXCEPT RATIOS) | |||||||||||||||||||||
| UNAUDITED | |||||||||||||||||||||
| Trailing Twelve | |||||||||||||||||||||
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Months | |||||||||||||||||
| Net Debt to Adjusted EBITDAS | |||||||||||||||||||||
| Net (Loss) Income | $ | (88,135 | ) | $ | (347,902 | ) | $ | 23,269 | $ | (46,192 | ) | $ | (458,960 | ) | |||||||
| Interest | 24,464 | 24,727 | 28,577 | 28,619 | 106,387 | ||||||||||||||||
| Taxes | 57,556 | 55,448 | (15,835 | ) | (27,342 | ) | 69,827 | ||||||||||||||
| Depreciation and Amortization | 10,007 | 10,403 | 9,545 | 9,155 | 39,110 | ||||||||||||||||
| Stock-based Compensation | 2,346 | 2,402 | 2,740 | 824 | 8,312 | ||||||||||||||||
| EBITDAS | $ | 6,238 | $ | (254,922 | ) | $ | 48,296 | $ | (34,936 | ) | $ | (235,324 | ) | ||||||||
| Franchise Rights Acquired and Goodwill Impairments | 3,633 | (1) | 257,988 | (2) | — | 57,045 | (3) | 318,666 | |||||||||||||
| 2024 Plan Restructuring Charges (4) | — | — | — | 14,812 | 14,812 | ||||||||||||||||
| 2023 Plan Restructuring Charges (5) | 23,140 | 5,493 | 1,910 | (749 | ) | 29,794 | |||||||||||||||
| 2022 Plan Restructuring Charges (6) | 489 | 244 | 69 | (257 | ) | 545 | |||||||||||||||
| Former CEO Separation Expenses (7) | — | — | — | 3,858 | 3,858 | ||||||||||||||||
| Adjusted EBITDAS | $ | 33,500 | $ | 8,803 | $ | 50,275 | $ | 39,773 | $ | 132,351 | |||||||||||
| Total Debt | $ | 1,429,598 | |||||||||||||||||||
| Less: Cash | 57,181 | ||||||||||||||||||||
| Net Debt | $ | 1,372,417 | |||||||||||||||||||
| Total Debt to Net Loss | (3.1 | ) | X | ||||||||||||||||||
| Net Debt to Adjusted EBITDAS | 10.4 | X | |||||||||||||||||||
| ____ | |||||||||||||||||||||
| Note: Totals may not sum due to rounding. | |||||||||||||||||||||
| (1) Impairment charges of the Company's goodwill of | |||||||||||||||||||||
| (2) Impairment charges of the Company's franchise rights acquired of | |||||||||||||||||||||
| (3) Impairment charges of the Company's franchise rights acquired of | |||||||||||||||||||||
| (4) Charges associated with the Company's previously disclosed 2024 restructuring plan. | |||||||||||||||||||||
| (5) Charges or the reversal of charges, as applicable, associated with the Company's previously disclosed 2023 restructuring plan. | |||||||||||||||||||||
| (6) Charges or the reversal of charges, as applicable, associated with the Company's previously disclosed 2022 restructuring plan. | |||||||||||||||||||||
| (7) Certain non-recurring expenses in connection with the separation from the Company of its former Chief Executive Officer. | |||||||||||||||||||||
| WW INTERNATIONAL, INC. AND SUBSIDIARIES | ||||||||||||||||
| RECONCILIATION OF NON-GAAP FINANCIAL MEASURES | ||||||||||||||||
| (IN THOUSANDS) | ||||||||||||||||
| UNAUDITED | ||||||||||||||||
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 28, | September 30, | September 28, | September 30, | |||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
| Adjusted Operating Income | $ | 35,664 | $ | 36,582 | $ | 67,969 | $ | 68,230 | ||||||||
| Other (Expense) Income, net | (5,870 | ) | (815 | ) | (4,187 | ) | 36 | |||||||||
| Depreciation and Amortization | 9,155 | 13,428 | 29,103 | 35,633 | ||||||||||||
| Stock-based Compensation | 824 | 3,225 | 5,966 | 8,956 | ||||||||||||
| Adjusted EBITDAS | $ | 39,773 | $ | 52,420 | $ | 98,851 | $ | 112,855 | ||||||||
| ____ | ||||||||||||||||
| Note: Totals may not sum due to rounding. | ||||||||||||||||
| WW INTERNATIONAL, INC. AND SUBSIDIARIES | ||
| RECONCILIATION OF NON-GAAP FINANCIAL MEASURES | ||
| (IN MILLIONS) | ||
| UNAUDITED | ||
| Full Year 2024 | ||
| Operating Income Guidance Reconciliation | ||
| Operating Loss | ||
| Franchise Rights Acquired Impairments (1) | ||
| Net Restructuring Charges (2) | ||
| Former CEO Separation Expenses (3) | ||
| Adjusted Operating Income | ||
| ____ | ||
| (1) Reflects the impairment charges of the Company's franchise rights acquired related to its United States, Australia, United Kingdom and New Zealand units of account in the first nine months of fiscal 2024. | ||
| (2) Reflects the net restructuring charges incurred in the first nine months of fiscal 2024 related to the Company's previously disclosed 2024 restructuring plan, 2023 restructuring plan and 2022 restructuring plan. | ||
| (3) Reflects certain non-recurring expenses in connection with the separation from the Company of its former Chief Executive Officer in the third quarter of fiscal 2024. | ||
FAQ
What was WW's revenue in Q3 2024?
How many subscribers did WW have at the end of Q3 2024?
What was WW's operating loss in Q3 2024?
What is WW's revenue guidance for full year 2024?
